Journal Mobile Options
Table of Contents
Vol. 62, Suppl. 1, 2000
Issue release date: July 2000
Digestion 2000;62(suppl 1):73–78

Chemotherapy in the Treatment of Neuroendocrine Malignant Tumors

Rougier P. · Mitry E.
Fédération des spécialités digestives, Service Hépato-gastroentérologie, Hôpital Ambroise-Paré, Boulogne, France

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


The efficacy of chemotherapy in digestive neuroendocrine tumors (NET) depends on primary site and histological differentiation. Many reports have suggested a superior activity of chemotherapy for pancreatic NET than for metastatic carcinoid tumors with response rates ranging from 40 to 60% compared to 20%. The standard chemotherapy for pancreatic NET is a combination of adriamycin and streptozocin and to a lesser extent a combination of 5FU and streptozocin. In contrast, there is no clear standard chemotherapy for carcinoid tumors and if most oncologists use a combination of 5FU and streptozocin in the case of advanced, progressive and nonresectable carcinoid tumors, the results are mostly poor and the benefit seldom counterbalances its toxicity. In these carcinoid tumors the combination of hepatic artery ischemia alternating with chemotherapy has given impressive results in one study, which, however, have never been confirmed. Tumor cell differentiation is a major prognostic factor and some reports have suggested a higher chemosensitivity for undifferentiated or poorly differentiated NET with tumor response rates ranging from 41 to 69% when a VP16-CDDP combination is used. This chemosensitivity is, unfortunately, as in small cell lung carcinomas, of short duration. Related to this special problem and the number of other active treatments in NET, the place of chemotherapy always has to be discussed in a multidisciplinary fashion. Surgical excision, chemoembolization, interferons and somatostatin analogues have to be emphasized and eventually combined with chemotherapy, especially in slowly growing tumors. New active chemotherapy regimens have to be tested clearly in this orphan group of tumors which does not hold much interest to the pharmaceutical companies.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Moertel CG: An odyssey in the land of small tumors. J Clin Oncol 1987;5:1503–1522.
  2. Harris AL: Chemotherapy for the carcinoid syndrome. Cancer Chemother Pharmacol 1981;5:133–138.

    External Resources

  3. Broder LR, Carter SK: Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients. Ann Intern Med 1973;79:108–118.

    External Resources

  4. Engstrom PF, Lavin PT, Moertel CG, Folsch E, Douglass HO: Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. J Clin Oncol 1984;2:1255–1259.
  5. Bukowski RM, Johnson KG, Peterson RF, Stephens RL, Rivkin SE, Neilan B, et al: A phase II trial of combination chemotherapy in patients with metastatic carcinoid tumors. A Southwest Oncology Group study. Cancer 1987;60:2891–2895.
  6. Moertel CG, Hanley JA: Combination therapy trials in metastatic carcinoid tumors and the malignant carcinoid syndrome. Cancer Clin Trials 1979;2:327–334.
  7. Kelsen DP, Cheng E, Kemeny N, Magill GB, Yagoda A: Streptozotocin and Adriamycin in the treatment of APUD tumors (carcinoid, islet cell and medullary carcinoma of the thyroid). Proc Am Assoc Cancer Res 1982;23:111.
  8. Haller DG, Schutt A, Dayal Y, Ryan L, Lipsitz S: Chemotherapy for metastatic carcinoid tumors: An ECOG phase II-III trial. Proc Am Soc Clin Oncol 1990;9:102.
  9. Rougier P, Oliveira J, Ducreux M, Theodore C, Kac J, Droz J-P: Metastatic carcinoid and islet cell tumors of the pancreas: A phase II trial of the efficacy of combination chemotherapy with 5-fluorouracil, doxorubicin and cisplatin. Eur J Cancer 1991;27:1380–1382.

    External Resources

  10. Elias D, Rougier P, Lasser P, Duvillard P, Venezia P, Schlumberger M, et al: Chirurgie majeure et chimiothérapies réductionnelles dans les apudomes polymétastatiques. Ann Chir 1988;42:474–481.

    External Resources

  11. Murray-Lyon IM, Eddelston ALWF, Williams R, Brown M, Hogbin BM, Bennett A, et al: Treatment of multiple hormone-producing malignant islet cell tumours with streptozotocin. Lancet 1968;ii:895–898.
  12. Moertel CG, Lavin P, Hahn G: Phase II trial of doxorubicin therapy for advanced islet cell carcinoma. Cancer Treat Rep 1987;66:1567–1569.
  13. Altimari A, Badrinath K, Reisel H, Prinz RA: DTIC therapy in patients with malignant intraabdominal neuroendocrine tumors. Surgery 1987;102:1009–1017.

    External Resources

  14. Eriksson B, Skogseid B, Lundqvist G, Wide L, Wilander E, Öberg K: Medical treatment and long-term survival in a prospective study of 84 patients with endocrine pancreatic tumors. Cancer 1990;65:1883–1890.
  15. Bukowski RM, Tangen C, Lee R, Macdonald JS, Einstein AB Jr, Peterson R, Fleming TR: Phase II trial of chlorozotocin and fluorouracil in islet cell carcinoma: A Southwest Oncology Group study. J Clin Oncol 1992;10:1914–1918.
  16. Moertel CG, Hanley JA, Johnsson LA: Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet cell carcinoma. N Engl J Med 1980;303:1189–1194.

    External Resources

  17. Moertel CG, Lefkopoulos M, Lipsitz M: Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992;326:519–523.
  18. Moertel CG, Kvols LK, O’Connell MJ, Rubin J: Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Cancer 1991;68:227–232.
  19. Seitz JF, Perrier H, Giovannini M, Monges G, Fourdan O, Barrière N, Viens P: Cancers neuroendocrines anaplasiques avancés: intérêt de l’association VP16-CDDP. Bull Cancer 1995;82:433–434.
  20. Mitry E, Baudin E, Ducreux M, Sabourin JC, Ruffié P, Aparicio T, Lasser P, Elias D, Duvillard P, Schlumberger M, Rougier P: Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 1999;81:1351–1355.
  21. Moertel CG, Johnson M, McKusick MA, Martin JK Jr, Nagorney DM, Kvols LK, et al: The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann Intern Med 1994;120:302–309.
  22. Lasser P, Elias D, Rougier Ph, Bonvallot S, Sabourin JC, Schlumberger M, Ducreux M, Roche A: Hépatectomies pour métastases de tumeurs neuro-endocrines (à propos de 17 cas). Gastroenterol Clin Biol 1996;20:A33.
  23. Öberg K: Neuroendocrine gastrointestinal tumours. Ann Oncol 1996;7:453–463.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50